- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2011.04738.x/abstract>
[英语研究
] [推荐]
停止抗病毒治疗
后预测乙肝炎复发的研究
Predictors of relapse in chronic hepatitis B after discontinuation of
anti-viral therapy
Y. Liang1, J. Jiang1, M. Su1, Z. Liu1, W. Guo1, X. Huang1, R. Xie1, S. Ge1,
J. Hu1, Z. Jiang1, M. Zhu1, V. W.-S. Wong2, H. L.-Y. Chan2
Article first published online: 14 JUN 2011
DOI: 10.1111/j.1365-2036.2011.04738.x
© 2011 Blackwell Publishing Ltd
Issue
Alimentary Pharmacology & Therapeutics
Volume 34, Issue 3, pages 344–352, August 2011
Aliment Pharmacol Ther 2011; 34: 344–352
Summary
Background Optimal duration of anti-viral therapy in chronic hepatitis B
virus (HBV) infection remains unclear.
Aim To investigate factors that could predict relapse after stopping
anti-viral agents.
Methods Chronic hepatitis B patients who were treated with anti-viral
agents (lamivudine, adefovir, entecavir) and have stopped the treatment
were recruited. Anti-viral agents were stopped according to the
recommendations of the Asian Pacific Association for the Study of the
Liver. Virological relapse was defined as an increase in serum HBV DNA to
> 1000 copies/mL after discontinuation of treatment.
Results Eighty-four (69 treatment naïve and 15 lamivudine resistant)
patients were eligible for this study. Thirty-seven patients developed
virological relapse at 4.3 ± 2.9 (range 1–11) months after
discontinuation of therapy. The 1-year cumulative probability of
virological relapse was 42% and 47% in HBeAg (hepatitis B e
antigen)-positive (n = 41) and HBeAg (hepatitis B e antigen)-negative (n =
43) patients, respectively. On multivariate analysis by Cox proportional
hazard model, pre-existing lamivudine resistance, delayed suppression of
HBV DNA to undetectable level during anti-viral therapy and to a higher
HBsAg (hepatitis B surface antigen) level at the end of treatment were
associated with virological relapse. Twelve of the 15 (80%) lamivudine
resistant patients developed virological relapse. Among the 11 treatment
naïve patients who had HBsAg ≤2 log IU/mL at the end of treatment, 1
(9%) of them had virological relapse.
Conclusions Treatment cessation among lamivudine resistant patients is
associated with high risk of virological relapse. Serum HBsAg level at the
end of treatment and rate of HBV DNA suppression can provide supplementary
information to guide the timing of stopping anti-viral drugs. |
|